Literature DB >> 18444857

Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit.

Jennifer K Chow1, Yoav Golan, Robin Ruthazer, Adolf W Karchmer, Yehuda Carmeli, Deborah Lichtenberg, Varun Chawla, Janet Young, Susan Hadley.   

Abstract

BACKGROUND: Candida albicans has been the most common cause of fungal bloodstream infections (BSIs) in intensive care units (ICUs); however, infections due to non-albicans Candida species have been increasing in prevalence. We examined factors associated with BSIs due to non-albicans Candida species, compared with C. albicans BSIs, in an ICU patient population.
METHODS: For our case-comparator study, we identified consecutive adult ICU patients with BSIs due to non-albicans Candida species or C. albicans at 2 tertiary care hospitals during the period 1995-2005. Data collected included demographic characteristics, comorbidities, exposure to antibiotics and antifungals, and ICU-related factors, such as total parenteral nutrition, blood product transfusions, invasive procedures, central venous catheter use, hemodialysis, and mechanical ventilation. We built a multivariable logistic regression model that identified variables that differentiate BSIs due to non-albicans Candida species from BSIs due to C. albicans.
RESULTS: There were 67 patients with BSIs due to non-albicans Candida species and 79 patients with C. albicans BSIs. Variables were adjusted for time at risk. In multivariable models, factors associated with an increased risk of BSIs due to non-albicans Candida species, compared with C. albicans BSIs, included fluconazole exposure (odds ratio, 11.6; 95% confidence interval, 2.28-58.8), central venous catheter exposure (odds ratio, 1.95; 95% confidence interval, 1.10-3.47), and mean number of antibiotics per day (odds ratio, 2.31; 95% confidence interval, 0.71-7.54). Total parenteral nutrition exposure was associated with a decreased risk (odds ratio, 0.16; 95% confidence interval, 0.05-0.47) of BSIs due to non-albicans Candida species, compared with C. albicans BSIs. Duration of stay in the ICU was not significantly different between the 2 groups. Specific antibiotics, such as vancomycin and piperacillin-tazobactam, were not independently associated with BSI due to non-albicans Candida species.
CONCLUSIONS: Receipt of fluconazole and central venous catheter exposure were associated with an increased risk of BSI due to non-albicans Candida species, and total parenteral nutrition was associated with a decreased risk of BSI due to non-albicans Candida species, compared with BSI due to C. albicans. Patients without characteristics of infection due to non-albicans Candida species might benefit from empirical antifungal therapy with fluconazole.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18444857     DOI: 10.1086/529435

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  65 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

2.  Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Authors:  Olivier Lortholary; Marie Desnos-Ollivier; Karine Sitbon; Arnaud Fontanet; Stéphane Bretagne; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 3.  Clinical aspects of invasive candidiasis in critically ill patients.

Authors:  Mariano Pennisi; Massimo Antonelli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

4.  Inactivation of the antifungal and immunomodulatory properties of human cathelicidin LL-37 by aspartic proteases produced by the pathogenic yeast Candida albicans.

Authors:  Maria Rapala-Kozik; Oliwia Bochenska; Marcin Zawrotniak; Natalia Wolak; Grzegorz Trebacz; Mariusz Gogol; Dominika Ostrowska; Wataru Aoki; Mitsuyoshi Ueda; Andrzej Kozik
Journal:  Infect Immun       Date:  2015-04-06       Impact factor: 3.441

Review 5.  Management of invasive candidiasis in nonneutropenic ICU patients.

Authors:  Emmanuel Weiss; Jean-François Timsit
Journal:  Ther Adv Infect Dis       Date:  2014-10

Review 6.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

7.  Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.

Authors:  Saad J Taj-Aldeen; Husam Salah; Winder B Perez; Muna Almaslamani; Mary Motyl; Atqah AbdulWahab; Kelley R Healey; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 8.  Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting.

Authors:  Brian D W Chow; Jennifer R Linden; Joseph M Bliss
Journal:  Expert Rev Anti Infect Ther       Date:  2012-08       Impact factor: 5.091

9.  Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.

Authors:  Maria Simitsopoulou; Pavla Peshkova; Efthymia Tasina; Aspasia Katragkou; Daniela Kyrpitzi; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

10.  Comparison of albicans vs. non-albicans candidemia in French intensive care units.

Authors:  Olivier Leroy; Jean-Paul Mira; Philippe Montravers; Jean-Pierre Gangneux; Olivier Lortholary
Journal:  Crit Care       Date:  2010-05-27       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.